168 related articles for article (PubMed ID: 32240559)
1. Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica.
Ma C; Wang S; Wang G; Wu Y; Yang T; Shen W; Zhuang Y; Zhang L; Liu X; Yang L; Feng Y; Yu Y; Liu Z; Wang D
J Clin Apher; 2020 Jun; 35(3):206-216. PubMed ID: 32240559
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population.
Ong ZM; Schee JP; Viswanathan S
Ther Apher Dial; 2020 Jun; 24(3):312-323. PubMed ID: 31654607
[TBL] [Abstract][Full Text] [Related]
4. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
5. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee.
Ipe TS; Raval JS; Fernando LP; Gokhale A; Jacquot C; Johnson AD; Kim HC; Monis GF; Mo YD; Morgan SM; Pagano MB; Pham HP; Sanford K; Schmidt AE; Schwartz J; Waldman A; Webb J; Winters JL; Wu Y; Yamada C; Wong ECC
J Clin Apher; 2020 Jan; 35(1):25-32. PubMed ID: 31705563
[TBL] [Abstract][Full Text] [Related]
7. Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica.
Pereira WLCJ; Reiche EMV; Kallaur AP; Oliveira SR; Simão ANC; Lozovoy MAB; Schiavão LJV; Rodrigues PRDVP; Alfieri DF; Flauzino T; Kaimen-Maciel DR
Acta Neuropsychiatr; 2017 Jun; 29(3):170-178. PubMed ID: 27692000
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorder and systemic lupus erythematosus.
Thabah MM; D S; Pranov R; Moulitej MMV; Ramesh A; Kadhiravan T
Lupus; 2019 Dec; 28(14):1722-1726. PubMed ID: 31722604
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.
Kinoshita M; Nakatsuji Y; Kimura T; Moriya M; Takata K; Okuno T; Kumanogoh A; Kajiyama K; Yoshikawa H; Sakoda S
Biochem Biophys Res Commun; 2009 Sep; 386(4):623-7. PubMed ID: 19545538
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.
Freitas E; Guimarães J
Rheumatol Int; 2015 Feb; 35(2):243-53. PubMed ID: 24952418
[TBL] [Abstract][Full Text] [Related]
11. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
Jarius S; Wildemann B
Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
[TBL] [Abstract][Full Text] [Related]
12. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.
Soltys J; Liu Y; Ritchie A; Wemlinger S; Schaller K; Schumann H; Owens GP; Bennett JL
J Clin Invest; 2019 Apr; 129(5):2000-2013. PubMed ID: 30958797
[TBL] [Abstract][Full Text] [Related]
13. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
[TBL] [Abstract][Full Text] [Related]
14. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
[TBL] [Abstract][Full Text] [Related]
15. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.
Duan T; Tradtrantip L; Phuan PW; Bennett JL; Verkman AS
Neuropharmacology; 2020 Jan; 162():107827. PubMed ID: 31654702
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and classification of neuromyelitis optica (Devic's syndrome).
Drori T; Chapman J
Autoimmun Rev; 2014; 13(4-5):531-3. PubMed ID: 24424197
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
Nicchia GP; Mastrototaro M; Rossi A; Pisani F; Tortorella C; Ruggieri M; Lia A; Trojano M; Frigeri A; Svelto M
Glia; 2009 Oct; 57(13):1363-73. PubMed ID: 19229993
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review.
Pereira WL; Reiche EM; Kallaur AP; Kaimen-Maciel DR
J Neurol Sci; 2015 Aug; 355(1-2):7-17. PubMed ID: 26050520
[TBL] [Abstract][Full Text] [Related]
19. High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG.
Miyazaki-Komine K; Takai Y; Huang P; Kusano-Arai O; Iwanari H; Misu T; Koda K; Mitomo K; Sakihama T; Toyama Y; Fujihara K; Hamakubo T; Yasui M; Abe Y
Br J Pharmacol; 2016 Jan; 173(1):103-14. PubMed ID: 26398585
[TBL] [Abstract][Full Text] [Related]
20. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.
Cayrol R; Saikali P; Vincent T
Ann N Y Acad Sci; 2009 Sep; 1173():478-86. PubMed ID: 19758189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
